Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for using Sifrol®, equivalent doses at the end of the switch and tolerability of Sifrol® in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Idiopathic Parkinson's disease patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sifrol® | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Reason for switch of therapy and reason for using Sifrol® | questionnaire | up to 8 weeks |
| Type of switch (abrupt or overlapping) | up to 8 weeks | |
| Changes in motor function by means of 5-points rating scale | Short Parkinson's Evaluation Scale (SPES) | up to 8 weeks |
| Changes in psychopathological memory disturbances by means of 5- point rating scale | Short Parkinson's Evaluation Scale (SPES) | up to 8 weeks |
| Changes in psychopathological thought disorder disturbances by means of 5- point rating scale | SPES score | up to 8 weeks |
| Changes in psychopathological depression disturbances by means of 5- point rating scale | SPES score | up to 8 weeks |
| Changes of mood on seven visual analogue scales (VASs) | assessed by patient | up to 8 weeks |
| Equivalent doses of Sifrol® | compared to previous treatment dosing, based on global clinical impression | after 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with adverse drug reactions | up to 8 weeks | |
| Assessment of tolerability by investigator on a 5-point rating scale | after 8 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Idiopathic Parkinson's disease patients recruited at office-based neurologists, psychiatrist or special neurology clinics
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077487 | Pramipexole |
| ID | Term |
|---|---|
| D052160 | Benzothiazoles |
| D013844 | Thiazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
| Global assessment of efficacy by investigator on a 5-point rating scale |
| after 8 weeks |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D006571 |
| Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |